Critical evaluation of hormonal therapy for carcinoma of the prostate (Q34758712)

4 August 2017

1 reference

title

Critical evaluation of hormonal therapy for carcinoma of the prostate (English)

1 reference

4 August 2017

Laurence Klotz

1 reference

ORCID Public Data File 2021

4 August 2017

1 reference

author name string

Gerald W Chodak

series ordinal

1 reference

4 August 2017

Thomas Keane

series ordinal

1 reference

4 August 2017

Hormone Therapy Study Group

series ordinal

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

201-208

1 reference

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Current methods of the US Preventive Services Task Force: a review of the process

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

The Value of Testosterone Deprivation in Stage D1 Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Early androgen deprivation for prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Stage D1 (T1-3, N1-3, M0) Prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Bicalutamide in the Treatment of Advanced Prostatic Carcinoma: A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Neoadjuvant hormonal therapy: the Canadian experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Pathologic changes associated with androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Survival of Patients with Incidentally Found Microscopic Cancer of the Prostate: Results of a Clinical Trial of Conservative Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901677-1

7 January 2021

10.1016/S0090-4295(02)01677-1

Identifiers

DOI

1 reference

4 August 2017

1 reference